Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26034975 | 0.82 | GLP1R (0.37) | GLP1RNOD1LPAR3LPAR1FAAH | |
| SCHEMBL26034893 | 0.80 | GLP1R (0.34) | GLP1RNOD1LPAR3 | |
| SCHEMBL27143004 | 0.79 | GLP1R (0.43) | GLP1RNOD1LPAR3LPAR1 | |
| SCHEMBL26035269 | 0.79 | GLP1R (0.35) | GLP1RNOD1LPAR3 | |
| SCHEMBL27117452 | 0.79 | GLP1R (0.42) | GLP1RNOD1LPAR3LPAR1 | |
| SCHEMBL26034986 | 0.78 | HRH3 (0.37) | GLP1RLPAR1MEN1FAAHKMT2A | |
| SCHEMBL25840094 | 0.75 | GLP1R (0.36) | GLP1RNOD1LPAR3LPAR1FAAH | |
| SCHEMBL26036004 | 0.74 | BIRC2 (0.39) | GLP1RNOD1LPAR3FAAH | |
| SCHEMBL26031954 | 0.73 | GLP1R (0.63) | GLP1RNOD1LPAR3LPAR1FAAH | |
| SCHEMBL26031980 | 0.73 | GLP1R (0.63) | GLP1RNOD1LPAR3LPAR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | GLP1R 1683/4885NOD1 4873/4885LPAR3 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.